Sarepta Therapeutics, Inc.

$SRPT is down about 40% and testing the lows of the stock for 2021 and 2022 after new data was released for its gene therapy to treat Ducchenne muscular dystrophy on Monday.

Share This Article

 

About the Author

Sarepta Therapeutics, Inc.

Joey Ramson